Cover Image
市場調查報告書

Flamel Technologies S.A. : 產品平台分析

Flamel Technologies S.A. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224580
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Flamel Technologies S.A. : 產品平台分析 Flamel Technologies S.A. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 33 Pages
簡介

Flamel Technologies S.A.是致力於開發可解決未滿足醫療需求的專業製藥公司,活用獨家藥物遞送技術平台來開發新化學物質 (NCEs) 及新生物學物質(NBEs)。

本報告提供Flamel Technologies S.A.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

Flamel Technologies S.A.的基本資料

Flamel Technologies S.A.概要

  • 主要資訊
  • 企業資料

Flamel Technologies S.A.:R&D概要

  • 主要的治療範圍

Flamel Technologies S.A.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Flamel Technologies S.A.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

Flamel Technologies S.A.:藥物簡介

  • GLP-1 biobetter
  • hydromorphone hydrochloride
  • sodium oxybate
  • somatropin biobetter
  • Drug for Cardiovascular Disorders
  • tigecycline biobetter
  • Proteins for Undisclosed Indication
  • Small Molecules for Undisclosed Indication

Flamel Technologies S.A.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Flamel Technologies S.A.:暫停中的計劃

Flamel Technologies S.A.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • interferon alfa-2b biobetter
    • interferon beta-1a biobetter

Flamel Technologies S.A.:企業發表

Flamel Technologies S.A.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07361CDB

Summary

Global Markets Direct's, 'Flamel Technologies S.A. - Product Pipeline Review - 2015', provides an overview of the Flamel Technologies S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Flamel Technologies S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Flamel Technologies S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Flamel Technologies S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Flamel Technologies S.A.'s pipeline products

Reasons to buy

  • Evaluate Flamel Technologies S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Flamel Technologies S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Flamel Technologies S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Flamel Technologies S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Flamel Technologies S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Flamel Technologies S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Flamel Technologies S.A. Snapshot
    • Flamel Technologies S.A. Overview
    • Key Information
    • Key Facts
  • Flamel Technologies S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Flamel Technologies S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Flamel Technologies S.A. - Pipeline Products Glance
    • Flamel Technologies S.A. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Flamel Technologies S.A. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Flamel Technologies S.A. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Flamel Technologies S.A. - Drug Profiles
    • GLP-1 biobetter
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hydromorphone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sodium oxybate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin biobetter
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Cardiovascular Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tigecycline biobetter
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Proteins for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Flamel Technologies S.A. - Pipeline Analysis
    • Flamel Technologies S.A. - Pipeline Products by Target
    • Flamel Technologies S.A. - Pipeline Products by Route of Administration
    • Flamel Technologies S.A. - Pipeline Products by Molecule Type
    • Flamel Technologies S.A. - Pipeline Products by Mechanism of Action
  • Flamel Technologies S.A. - Recent Pipeline Updates
  • Flamel Technologies S.A. - Dormant Projects
  • Flamel Technologies S.A. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • interferon alfa-2b biobetter
      • interferon beta-1a biobetter
  • Flamel Technologies S.A. - Company Statement
  • Flamel Technologies S.A. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Flamel Technologies S.A., Key Information
  • Flamel Technologies S.A., Key Facts
  • Flamel Technologies S.A. - Pipeline by Indication, 2015
  • Flamel Technologies S.A. - Pipeline by Stage of Development, 2015
  • Flamel Technologies S.A. - Monotherapy Products in Pipeline, 2015
  • Flamel Technologies S.A. - Partnered Products in Pipeline, 2015
  • Flamel Technologies S.A. - Partnered Products/ Combination Treatment Modalities, 2015
  • Flamel Technologies S.A. - Phase I, 2015
  • Flamel Technologies S.A. - Preclinical, 2015
  • Flamel Technologies S.A. - Unknown, 2015
  • Flamel Technologies S.A. - Pipeline by Target, 2015
  • Flamel Technologies S.A. - Pipeline by Route of Administration, 2015
  • Flamel Technologies S.A. - Pipeline by Molecule Type, 2015
  • Flamel Technologies S.A. - Pipeline Products by Mechanism of Action, 2015
  • Flamel Technologies S.A. - Recent Pipeline Updates, 2015
  • Flamel Technologies S.A. - Dormant Developmental Projects,2015
  • Flamel Technologies S.A. - Discontinued Pipeline Products, 2015
  • Flamel Technologies S.A., Subsidiaries

List of Figures

  • Flamel Technologies S.A. - Pipeline by Top 10 Indication, 2015
  • Flamel Technologies S.A. - Pipeline by Stage of Development, 2015
  • Flamel Technologies S.A. - Monotherapy Products in Pipeline, 2015
  • Flamel Technologies S.A. - Partnered Products in Pipeline, 2015
  • Flamel Technologies S.A. - Pipeline by Top 10 Target, 2015
  • Flamel Technologies S.A. - Pipeline by Top 10 Route of Administration, 2015
  • Flamel Technologies S.A. - Pipeline by Top 10 Molecule Type, 2015
  • Flamel Technologies S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top